Edgewise Therapeutics Inc...
27.55
2.22 (8.76%)
At close: Jan 14, 2025, 3:59 PM
29.80
8.17%
Pre-market Jan 15, 2025, 04:09 AM EST
undefined%
Bid 11.01
Market Cap 2.61B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.5
PE Ratio (ttm) -18.37
Forward PE n/a
Analyst Buy
Ask 29.98
Volume 1,744,737
Avg. Volume (20D) 800,331
Open 25.75
Previous Close 25.33
Day's Range 24.95 - 27.87
52-Week Range 9.00 - 38.12
Beta undefined

About EWTX

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that t...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 26, 2021
Employees 108
Stock Exchange NASDAQ
Ticker Symbol EWTX

Analyst Forecast

According to 6 analyst ratings, the average rating for EWTX stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 81.49% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
1 month ago · Source
+18.36%
Edgewise Therapeutics shares are trading higher af... Unlock content with Pro Subscription
2 months ago · Source
-3.25%
Edgewise Therapeutics shares are trading lower. The company reported Q3 financial results.